Science & Technology Watch
SEE OTHER BRANDS

Your science and technology news reporter

Science & Technology Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science & Technology Watch.

Press releases published on July 15, 2025

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for …

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area

- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) …

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for …

Neuronetics Appoints New Chief Financial Officer

Neuronetics Appoints New Chief Financial Officer

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second …

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE …

WestKam Gold Corp. Provides Update on Management Cease Trade Order,  Announces Appointment of Interim CFO and Announces Private Placement

WestKam Gold Corp. Provides Update on Management Cease Trade Order, Announces Appointment of Interim CFO and Announces Private Placement

Vancouver, BC, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- WestKam Gold Corp. (TSXV:WKG) (the “Company” or “WestKam”), further to its news release of July 2, 2025 (the “MCTO Announcement”), provides an update with respect to the management cease trade order …

AAS MINER Launches AI-Powered Bitcoin Cloud Mining — Activate with BTC, ETH, DOGE, or XRP for Higher Returns

AAS MINER Launches AI-Powered Bitcoin Cloud Mining — Activate with BTC, ETH, DOGE, or XRP for Higher Returns

LONDON, UK, July 15, 2025 (GLOBE NEWSWIRE) -- A Smarter Future for Bitcoin Mining Starts Now The landscape of Bitcoin mining is changing—fast. Gone are the days when mining was limited to tech-savvy users and expensive hardware. AAS MINER is ushering in a …

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is informed by results of a 6,000 nationwide patient …

CECO Environmental to Release Second Quarter Earnings and Host Conference Call on July 29

CECO Environmental to Release Second Quarter Earnings and Host Conference Call on July 29

ADDISON, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that it …

TopBuild Completes Progressive Roofing Acquisition

TopBuild Completes Progressive Roofing Acquisition

Aligns with TopBuild’s Core Strengths Expands Building Envelope Offering to General Contractor Customers and Increases Exposure to Non-Cyclical and Non-Discretionary Revenue Drivers Establishes Scalable Platform for Growth in $75 Billion, Highly Fragmented …

AAFA Names Matthew Greenhawt Chief Medical Officer

AAFA Names Matthew Greenhawt Chief Medical Officer

Washington, DC, July 15, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) today announced that Matthew Greenhawt, MD, MBA, MSc, has joined the organization as Chief Medical Officer. In this new role, Dr. Greenhawt will help …

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology Preclinical candidate data expected in early 2026, with …

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

- Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen - Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHOU, China, July 15 …

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutation CELESTE is informed by the STELLA prospective natural history study, which is currently enrolling …

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held …

Verano Announces Promotion and Appointment of James Leventis as Chief Strategy and Compliance Officer

Verano Announces Promotion and Appointment of James Leventis as Chief Strategy and Compliance Officer

CHICAGO, July 15, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the promotion and appointment of James Leventis as the Company’s Chief …

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

New Drug Submission meeting scheduled with Health Canada for the third quarter of 2025 Initial briefing book submitted for review to the European Medicines Agency WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) …

Accelsius Brings NeuCool™ to Equinix’s Co-Innovation Facility in Ashburn

Accelsius Brings NeuCool™ to Equinix’s Co-Innovation Facility in Ashburn

AUSTIN, Texas, July 15, 2025 (GLOBE NEWSWIRE) -- Accelsius, a leader in advanced data center cooling solutions, announced that its proprietary NeuCool™ IR80 system will be deployed in Q3 2025 at Equinix’s Co-Innovation Facility (CIF) in the DC15 …

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

PyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata Steel

MONTREAL, July 15, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), a high-tech company that designs, develops, manufactures and commercializes advanced all-electric plasma processes …

Mirasol Signs Agreement for the Sale of the Nord Projects in Chile for US$2.5 Million Plus Royalty

Mirasol Signs Agreement for the Sale of the Nord Projects in Chile for US$2.5 Million Plus Royalty

Eco Earth to acquire the Nord East and Nord West Projects for a total combined consideration of ~US$2.5 million over 4 years of scheduled payments Mirasol will retain a 2% NSR royalty on Nord East, Eco Earth will have the right to purchase the first 1% for …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions